Biopool Will Evaluate Blood Test Technology
- Share via
Biopool International in Ventura has entered into an agreement with the Research Foundation of the State University of New York to evaluate certain inventions and know-how relating to clotting tests.
The agreement allows Biopool to receive information from the inventors, Dr. Scott Diamond and associates at SUNY-Buffalo, and evaluate the technology for six months. If Biopool wishes, the parties then will negotiate a definitive license agreement.
The patent application says the inventions use fluorescent-labeled proteins to detect biological reactions such as clotting.
“It is our interest to evaluate the technology for key hemostasis proteins to make [Biopool’s test kits] more sensitive, easier, quicker and more broadly available to the clinical laboratory,” said Michael D. Bick, Biopool chairman and chief executive officer. “Furthermore, if we are successful in applications for hemostasis tests, the technology may have broad applications to many other enzymes and related proteins that are commonly tested in the clinical laboratory.”
Biopool develops and manufactures test kits to assess and diagnose various blood disorders.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
